Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix

Acta Oncologica

Volumn 38, Issue 4, 1999, Pages 517-520

  Marth, Christian ^a,b   Sundfor, Kolbein ^a   Kaern, Janne ^a   Tropé, Claes ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CREATININE; FLUOROURACIL;

ADJUVANT CHEMOTHERAPY; ADULT; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OTOTOXICITY; PRIORITY JOURNAL; RADICAL HYSTERECTOMY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; UTERINE CERVIX CARCINOMA;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE PROGRESSION; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 0033016975     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/028418699432077     Document Type: Article

References (25)

1. 1. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-40.
2. 2. Piver MS, Chung WS. Prognostic significance of cervical lesion size and pelvic node metastases in cervical carcinoma. Obstet Gynecol 1975; 46: 507-10.
3. 3. Hoskins W. Prognostic factors for risk of recurrence in stage Ib and IIa cervical cancer. In: Burghardt E, Monagham JM, eds. Clinical obstetrics and gynecology. London: Baillière-Tindal, 1989: 817.
4. 4. Fuller AF, Elliot HN, Kosloff C, et al. Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage Ib and IIa carcinoma of the cervix. Gynecol Oncol 1989; 33: 34-9.
5. 5. Landoni F, Milani R, Colombo A, et al. Cancer of the cervix, FIGO stages Ib and IIa: patterns of local growth and paracervical extension. Int J Gynecol Cancer 1995; 5: 329-34.
6. 6. Alberts DS, Garcia DJ. Salvage chemotherapy in recurrent or refractory squamous cell cancer of the uterine cervix. Semin Oncol 1994; 21: 37-46.
7. 7. Sardi J, di Paola G, Giarioli A, et al. Four years' experience in the treatment of carcinoma of the cervix uteri with neoadjuvant chemotherapy. Baillieres Clin Obstet Gynaecol 1988; 2: 1037-47.
8. 8. Baltzer J, Köpcke W. Tumor size and lymph node metastases in squamous cell carcinoma of the uterine cervix. Arch Gynecol 1979; 227: 271-8.
9. 9. Kaern J, Tropé C, Sundfør K, Kristensen GB. Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up. Gynecol Oncol 1996; 60: 387-92.
10. 10. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol 1974; 44: 265-72.
11. 11. di Paola G, Sardi J. Prospective randomized trial with neoadjuvant chemotherapy in stage IB bulky squamous carcinoma of the uterine cervix. Gynecol Oncol 1995; 59: 165.
12. 12. Zanetta G, Lissoni A, Gabriele A, et al. Intense neoadjuvant chemotherapy with cisplatin and epirubicin for advanced or bulky cervical and vaginal adenocarcinoma. Gynecol Oncol 1997; 64: 431-5.
13. 13. Lai CH, Hsueh S, Chang TS. Prognostic factors in patients with bulky stage IB or IIA cervical carcinoma undergoing neoadjuvant chemotherapy and radical hysterectomy. Gynecol Oncol 1997; 64: 456-62.
14. 14. Serur E, Mathews RP, Gates J. Neoadjuvant chemotherapy in stage IB2 squamous cell carcinoma of the cervix. Gynecol Oncol 1997; 65: 348-56.
15. 15. Bolis G, van Zainten-Przybysz I, Scartone G, et al. Determinants of response to a cisplatin-based regimen as neoadjuvant chemotherapy in stage IB-IIB invasive cervical cancer. Gynecol Oncol 1996; 63: 62-5.
16. 16. Eddy GL, Manetta A, Alvarez RD, et al. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol 1995; 57: 412-6.
17. 17. Eddy Sr GL. Neoadjuvant chemotherapy before surgery in cervical cancer. J Natl Cancer Inst Monogr 1996; 21: 93-9.
18. 18. Sardi J, Sananes C, Giaroli A, et al. Results of a prospective randomized trial with neoadjuvant chemotherapy in stage IB, bulky, squamous carcinoma of the cervix. Gynecol Oncol 1993; 49: 156-65.
19. 19. Sardi J, Sananes C, Giaroli A, et al. Neoadjuvant chemotherapy in locally advanced carcinoma of the cervix uteri. Gynecol Oncol 1990; 38: 486-93.
20. 20. Panici PB, Greggi S, Scambani G, et al. High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 1991; 41: 212-6.
21. 21. Benedetti-Panici P, Greggi S, Scambia G, et al. Cisplatin (P), bleomycin (B), and methotrexate (M) preoperative chemotherapy in locally advanced vulvar carcinoma. Gynecol Oncol 1993; 50: 49-53.
22. 22. Dottino PR, Segna RA. Neoadjuvant chemotherapy in cervix cancer. Cancer Treat Res 1994; 70: 63-71.
23. 23. Kim BG, Kim JH, Park SY, et al. Relationship between squamous cell carcinoma antigen levels and tumor volumes in patients wilh cervical carcinomas undergoing neoadjuvant chemotherapy. Gynecol Oncol 1996; 63: 105-13.
24. 24. Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. Gynecol Oncol 1997; 67: 61-9.
25. 25. Sundfør K, Tropé CG, Högberg T, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 1996; 77: 2371-8.